Value of intravoxel incoherent motion in detecting and staging liver fibrosis: A meta-analysis

Table 1 Baseline characteristics of the included studies and subjects

Ref.	Year	Country	Study design	Sample size	Sex ratio, M/F	mean ± SD age in yr	Patient spectrum (n)
Yoon et al[30]	2019	South Korea	Retro	106	81/25	55.4 ± 11.6	HBV (82), HCV (9), non-B non-C cirrhosis (3), ALD (10), PBC (2)
Fu et al[25]	2019	China	Pros	125	71/54	37.6 ± 9.3 (patients), 31.5 ± 12.9 (volunteers)	HBV (81), HCV (8), NAFLD (3), DIH (2), AIH (6)
Zawada et al[34]	2019	Poland	Pros	40	10/30	22-75	HCV (40)
Sandrasegaran et al[32]	2018	United States	Retro	49	35/14	56.6 (range: 32–73)	HBV (3), HCV (35), ALD (24), AIH (4), Other (7)1
Seo et al[31]	2018	South Korea	Retro	95	70/25	59.5 ± 9.5	HBV (44), HCV (7), ALD (14), no underlying liver disease (30)
Hu et al[29]	2017	China	Retro	56	14/42	47.48 (range: 15–76)	HBV (5), NAFLD (14), ASH (1), PSC (8), AIH (10), overlap syndrome of AIH (5), and DIH (13)
Chung et al[35]	2015	South Korea	Retro	57	35/22	58.7 (range: 32–89)	HBV (34), HCV (1), ALD (2), Other (20)
Wu et al[27]	2015	China (Taiwan)	Pros	49	36/13	62.4 (range: 38–85)	HBV (17), HVC (10), non-B non-C carriers (17), both hepatitis B and C carriers (5)
Ichikawa et al[26]	2015	Japan	Retro	182	127/55	66.4 ± 11.6	HBV (18), HCV (62), ASH (12), NASH (3), AIH (1), PBC (2), unidentified liver disease with an elevated liver enzyme level (12)
Parente et al[28]	2015	Brazil	Pros	59	10/49	54 ± 9	Type 2 diabetic subjects (59)
Chen et al[24]	2014	China	Pros	50	37/13	43.7 ± 1.2 (patients), 38.9 ± 1.3 (volunteers)	HBV (15), HCV (1), ALD (1), unidentified liver disease with an elevated liver enzyme level (8)
Yoon et al[33]	2014	South Korea	Retro	55	42/13	53.9 (range: 18–78)	HBV (45), HCV (1), ALD (1), Other (8)

¹Some patients had more than one etiology of liver disease. M/F: Male/female; SD: Standard deviation; Retro: Retrospective; Pros: Prospective; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; PBC: Primary biliary cirrhosis; PSC: Primary sclerotic cholangitis; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; DIH: Drug-induced hepatitis; AIH: Autoimmune hepatitis; ASH: Alcoholic steatohepatitis.